Delivery of mengovirus-derived RNA replicons into tumoural liver enhances the anti-tumour efficacy of a peripheral peptide-based vaccine

Cancer Immunology, Immunotherapy

Volumn 57, Issue 8, 2008, Pages 1161-1171

  Couty, Jean Pierre ^a,b,c   Crain, Anne Marie ^a,b,c   Gerbaud, Sylvie ^b,c   Labasque, Marilyne ^a,b,c   Marchiol, Carmen ^a,b,c   Fradelizi, Didier ^a,b,c   Boudaly, Sarah ^c,d   Guettier, Catherine ^e   Vignuzzi, Marco ^b,c   Van Der Werf, Sylvie ^b,c   Escriou, Nicolas ^b,c   Viguier, Mireille ^a,b,c  

^a INSERM   (France)

^b CNRS   (France)

^c UNIVERSITÉ PARIS DESCARTES   (France)

^d PSL RESEARCH UNIVERSITY   (France)

^e HÔPITAL PAUL BROUSSE   (France)

Author keywords

Animal model; Cytotoxic T cells; Hepatocellular carcinoma (HCC); Immunotherapy; RNA replicons; Tumour stroma

Indexed keywords

CANCER VACCINE; PEPTIDE DERIVATIVE; TUMOR ANTIGEN; VIRUS RNA;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER IMMUNIZATION; CD8+ T LYMPHOCYTE; CELL SUBPOPULATION; CELLULAR IMMUNITY; CONTROLLED STUDY; DRUG EFFICACY; HUMAN; HUMAN CELL; INNATE IMMUNITY; LIVER CELL CARCINOMA; LIVER PARENCHYMA; LIVER TUMOR; LYMPHOCYTE SUBPOPULATION; LYMPHOID CELL; MALE; MENGO VIRUS; MOUSE; NATURAL KILLER CELL; NATURAL KILLER T CELL; NONHUMAN; PRIORITY JOURNAL; REPLICON; RNA REPLICATION; RNA SEQUENCE; SIMIAN VIRUS 40; TREATMENT RESPONSE; TUMOR REGRESSION;

ANIMALS; CANCER VACCINES; CARCINOMA, HEPATOCELLULAR; DISEASE MODELS, ANIMAL; FLOW CYTOMETRY; HISTOCOMPATIBILITY ANTIGENS CLASS I; IMMUNOTHERAPY; LIVER NEOPLASMS; MALE; MENGOVIRUS; MICE; MICE, INBRED C57BL; PEPTIDES; REPLICON; RNA, VIRAL; TREATMENT OUTCOME;

EID: 44249104488     PISSN: 03407004     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00262-007-0448-3     Document Type: Article

References (39)

1. Baratin M, Ziol M, Romieu R, Kayibanda M, Gouilleux F, Briand P, Leroy P, Haddada H, Renia L, Viguier M, Guillet JG (2001) Regression of primary hepatocarcinoma in cancer-prone transgenic mice by local interferon-gamma delivery is associated with macrophages recruitment and nitric oxide production. Cancer Gene Ther 8:193-202
2. Belnoue E, Guettier C, Kayibanda M, Le Rond S, Crain-Denoyelle AM, Marchiol C, Ziol M, Fradelizi D, Renia L, Viguier M (2004) Regression of established liver tumor induced by monoepitopic peptide-based immunotherapy. J Immunol 173:4882-4888
3. Chiriva-Internati M, Grizzi F, Jumper CA, Cobos E, Hermonat PL, Frezza EE (2005) Immunological treatment of liver tumors. World J Gastroenterol 11:6571-6576
4. Cornet S, Menez-Jamet J, Lemonnier F, Kosmatopoulos K, Miconnet I (2006) CpG oligodeoxynucleotides activate dendritic cells in vivo and induce a functional and protective vaccine immunity against a TERT derived modified cryptic MHC class I-restricted epitope. Vaccine 24:1880-1888
5. Crettaz J, Berraondo P, Mauleon I, Ochoa L, Shankar V, Barajas M, van Rooijen N, Kochanek S, Qian C, Prieto J et al (2006) Intrahepatic injection of adenovirus reduces inflammation and increases gene transfer and therapeutic effect in mice. Hepatology 44:623-632
6. Crowe NY, Coquet JM, Berzins SP, Kyparissoudis K, Keating R, Pellicci DG, Hayakawa Y, Godfrey DI, Smyth MJ (2005) Differential antitumor immunity mediated by NKT cell subsets in vivo. J Exp Med 202:1279-1288
7. Dalemans W, Delers A, Delmelle C, Denamur F, Meykens R, Thiriart C, Veenstra S, Francotte M, Bruck C, Cohen J (1995) Protection against homologous influenza challenge by genetic immunization with SFV-RNA encoding Flu-HA. Ann N Y Acad Sci 772:255-256
8. Donnelly JJ, Friedman A, Ulmer JB, Liu MA (1997) Further protection against antigenic drift of influenza virus in a ferret model by DNA vaccination. Vaccine 15:865-868
9. Donnelly JJ, Ulmer JB, Liu MA (1998) DNA vaccines. Dev Biol Stand 95:43-53
10. Dudley ME, Rosenberg SA (2003) Adoptive-cell-transfer therapy for the treatment of patients with cancer. Nat Rev Cancer 3:666-675
11. Dudley ME, Wunderlich JR, Shelton TE, Even J, Rosenberg SA (2003) Generation of tumor-infiltrating lymphocyte cultures for use in adoptive transfer therapy for melanoma patients. J Immunother 26:332-342
12. Garbi N, Arnold B, Gordon S, Hammerling GJ, Ganss R (2004) CpG motifs as proinflammatory factors render autochthonous tumors permissive for infiltration and destruction. J Immunol 172:5861-5869
13. Gurunathan S, Irvine KR, Wu CY, Cohen JI, Thomas E, Prussin C, Restifo NP, Seder RA (1998) CD40 ligand/trimer DNA enhances both humoral and cellular immune responses and induces protective immunity to infectious and tumor challenge. J Immunol 161:4563-4571
14. Irvine KR, Rao JB, Rosenberg SA, Restifo NP (1996) Cytokine enhancement of DNA immunization leads to effective treatment of established pulmonary metastases. J Immunol 156:238-245
15. Kawarada Y, Ganss R, Garbi N, Sacher T, Arnold B, Hammerling GJ (2001) NK- and CD8 (+) T cell-mediated eradication of established tumors by peritumoral injection of CpG-containing oligodeoxynucleotides. J Immunol 167:5247-5253
16. Laddy DJ, Weiner DB (2006) From plasmids to protection: a review of DNA vaccines against infectious diseases. Int Rev Immunol 25:99-123
17. Lobert PE, Escriou N, Ruelle J, Michiels T (1999) A coding RNA sequence acts as a replication signal in cardioviruses. Proc Natl Acad Sci USA 96:11560-11565
18. Martinon F, Krishnan S, Lenzen G, Magne R, Gomard E, Guillet JG, Levy JP, Meulien P (1993) Induction of virus-specific cytotoxic T lymphocytes in vivo by liposome-entrapped mRNA. Eur J Immunol 23:1719-1722
19. Miyagi T, Takehara T, Tatsumi T, Suzuki T, Jinushi M, Kanazawa Y, Hiramatsu N, Kanto T, Tsuji S, Hori M, Hayashi N (2004) Concanavalin a injection activates intrahepatic innate immune cells to provoke an antitumor effect in murine liver. Hepatology 40:1190-1196
20. Monsurro V, Nagorsen D, Wang E, Provenzano M, Dudley ME, Rosenberg SA, Marincola FM (2002) Functional heterogeneity of vaccine-induced CD8 (+) T cells. J Immunol 168:5933-5942
21. Motola-Kuba D, Zamora-Valdes D, Uribe M, Mendez-Sanchez N (2006) Hepatocellular carcinoma. An overview. Ann Hepatol 5:16-24
22. Mueller MM, Fusenig NE (2004) Friends or foes-bipolar effects of the tumour stroma in cancer. Nat Rev Cancer 4:839-849
23. Ohshita A, Yamaguchi Y, Minami K, Okita R, Toge T (2006) Generation of tumor-reactive effector lymphocytes using tumor RNA-introduced dendritic cells in gastric cancer patients. Int J Oncol 28:1163-1171
24. Osorio JE, Hubbard GB, Soike KF, Girard M, van der Werf S, Moulin JC, Palmenberg AC (1996) Protection of non-murine mammals against encephalomyocarditis virus using a genetically engineered Mengo virus. Vaccine 14:155-161
25. Romieu R, Baratin M, Kayibanda M, Guillet JG, Viguier M (1998) IFN-gamma-secreting Th cells regulate both the frequency and avidity of epitope-specific CD8+ T lymphocytes induced by peptide immunization: an ex vivo analysis. Int Immunol 10:1273-1279
26. + T cell-based immunotherapy interferes with liver tumor progression in a transgenic mouse model. J Immunol 161:5133-5137
27. Rosenberg SA, Yang JC, Restifo NP (2004) Cancer immunotherapy: moving beyond current vaccines. Nat Med 10:909-915
28. Schell TD, Tevethia SS (2001) Control of advanced choroid plexus tumors in SV40 T antigen transgenic mice following priming of donor CD8 (+) T lymphocytes by the endogenous tumor antigen. J Immunol 167:6947-6956
29. Sette A, Vitiello A, Reherman B, Fowler P, Nayersina R, Kast WM, Melief CJ, Oseroff C, Yuan L, Ruppert J, et al. (1994) The relationship between class I binding affinity and immunogenicity of potential cytotoxic T cell epitopes. J Immunol 153:5586-5592
30. Speiser DE, Lienard D, Rufer N, Rubio-Godoy V, Rimoldi D, Lejeune F, Krieg AM, Cerottini JC, Romero P (2005) Rapid and strong human CD8+ T cell responses to vaccination with peptide, IFA, and CpG oligodeoxynucleotide 7909. J Clin Invest 115:739-746
31. Tagawa ST, Cheung E, Banta W, Gee C, Weber JS (2006) Survival analysis after resection of metastatic disease followed by peptide vaccines in patients with stage IV melanoma. Cancer 106:1353-1357
32. Terabe M, Swann J, Ambrosino E, Sinha P, Takaku S, Hayakawa Y, Godfrey DI, Ostrand-Rosenberg S, Smyth MJ, Berzofsky JA (2005) A nonclassical non-Valpha14Jalpha18 CD1d-restricted (type II) NKT cell is sufficient for down-regulation of tumor immunosurveillance. J Exp Med 202:1627-1633
33. Ulmer JB, Wahren B, Liu MA (2006) Gene-based vaccines: recent technical and clinical advances. Trends Mol Med 12:216-222
34. Vignuzzi M, Gerbaud S, van der Werf S, Escriou N (2001) Naked RNA immunization with replicons derived from poliovirus and Semliki Forest virus genomes for the generation of a cytotoxic T cell response against the influenza A virus nucleoprotein. J Gen Virol 82:1737-1747
35. Wu S, Wang SQ, Zhang J, Tan XY, Liu JN (2006) Native anti-tumor responses elicited by immunization with a low dose of unmodified live tumor cells. Int J Oncol 28:731-736
36. Ying H, Zaks TZ, Wang RF, Irvine KR, Kammula US, Marincola FM, Leitner WW, Restifo NP (1999) Cancer therapy using a self-replicating RNA vaccine. Nat Med 5:823-827
37. Yu P, Lee Y, Liu W, Chin RK, Wang J, Wang Y, Schietinger A, Philip M, Schreiber H, Fu YX (2004) Priming of naive T cells inside tumors leads to eradication of established tumors. Nat Immunol 5:141-149
38. Zhou J, Dudley ME, Rosenberg SA, Robbins PF (2004) Selective growth, in vitro and in vivo, of individual T cell clones from tumor-infiltrating lymphocytes obtained from patients with melanoma. J Immunol 173:7622-7629
39. Zhou X, Berglund P, Rhodes G, Parker SE, Jondal M, Liljestrom P (1994) Self-replicating Semliki Forest virus RNA as recombinant vaccine. Vaccine 12:1510-1514